According to Future Market Insights research, during the projected period, the global orthopedic oncology market is expected to grow at a CAGR of 6.5%. The market value is projected to increase from US$ 1.2 Billion in 2023 to US$ 2.3 Billion by 2033. The orthopedic oncology market was valued at US$ 1.1 Billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 7.2% in 2023.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 1.1 Billion |
| Market Value 2023 | US$ 1.2 Billion |
| Market Value 2033 | US$ 2.3 Billion |
| CAGR 2023 to 2033 | 6.5% |
| Market Share of Top 5 Countries | 54.1% |
| Key Market Players | General Electric (GE) Healthcare, Siemens Healthineers, Koninklijke Philips N.V., Hitachi Medical Systems, Hologic, Shimadzu Medical Systems, Carestream Health, Canon Medical Systems, FUJIFILM Medical Systems, Ziehm Imaging, Planmed Oy, EOS imaging, Medtronic plc, Stryker Corporation, Cook Medical, Zimmer Biomet, Biopsybell, Becton Dickenson & Company, and Teleflex Inc. |
Orthopedic oncology is a specialized field of medicine which focuses on diagnosing and treatment of bone and soft tissue tumors, both benign and malignant, within the musculoskeletal system. The orthopedic oncology market is driven by multiple factors such as increasing incidences of bone and soft tissue tumours, and advancements in diagnostic techniques and treatment modalities. The field involves orthopedic surgeons, radiologists, and pathologists to give comprehensive care to patients with bone and soft tissue cancer.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for orthopedic oncology was around 0.6% of the overall US$ 191.3 Billion of the global cancer diagnostics market in 2022. The diagnostics of orthopedic oncology expanded at a CAGR of 6.3% from 2017–2022, due to the increasing cases of musculoskeletal cancer.
Orthopedic oncology emerged as a distinct field in the late 1960s and early 1970s when orthopedic surgeons recognized the need for specialized care for patients with bone and soft tissue tumors. The development of advanced imaging techniques such as magnetic resonance imaging (MRI) and computed tomography (CT) scans greatly improved the ability to diagnose and stage tumors accurately, enabling better treatment planning.
Several macroeconomic factors have been affecting the market among which healthcare spending has had a crucial impact on the market.
According to the journal Inquiry 2019, healthcare spending on treatment for cancer has also risen dramatically during the last two decades. Cancer research has resulted in advancements in the early detection and management of cancer during the last several decades, leading to decreases in overall mortality and incidence attributable to cancer.
According to data from the Agency for Healthcare Research and Quality, $57 billion was invested in treatment for cancer in 2001, rising to $88.3 billion in 2011,8 and the National Cancer Institute predicted that national projections of cancer care expenses might reach $173 billion by 2020.
Musculoskeletal tumours represent an uncommon and diverse group of tumours. Sarcomas of the bone and cartilage account for less than one per cent of all cancers in humans. Their prevalence is much higher in youngsters than in adults. The market is affected by the availability of innovative treatment options including targeted therapies and immunotherapies. The number of cancer patients globally is increasing, and technological developments such as image reconstruction programmes, imaging equipment, biomarkers, as well as artificial intelligence algorithms are helping in imaging techniques and surgical techniques are influencing the orthopedic oncology industry.
Techniques such as magnetic resonance imaging (MRI) and computed tomography (CT) scan aid in tumour diagnosis and assessment, while limb-salvage surgeries and reconstructive procedures have improved patients' health. The orthopedic oncology market is likely to expand in the future years, owing to factors such as the rising prevalence of bone and soft tissue tumours, technological developments, and the development of novel treatment options.
Principal Consultant
High treatment expenses, including surgeries, radiation therapy, and chemotherapy, are one of the factors that could limit the growth of the orthopedic oncology market. Patients face financial constraints as a result, limiting their access to effective care, particularly in underdeveloped nations. Another issue will be the scarcity of clinical data and research possibilities. The lack of cutting-edge medicines for patients and poor progress in cancer research impede the development of new treatment choices and creative remedies.
The USA occupies 26.2% share in global market in 2022.
According to the American Cancer Society 2021, Americans are at risk of chondrosarcoma for a variety of causes, including advanced age, enchondroma or multiple enchondromatosis, which is connected to mutations in the IDH1 or IDH2 genes. People who have received radiation therapy (typically to treat another type of cancer) have an increased risk of acquiring bone cancer, according to the Centre for Disease Control and Prevention 2020.
These factors make the USA population more favourable to the orthopedic oncology market. Along with this USA has a well-developed healthcare system with advanced medical infrastructure for the diagnosis and treatment of tumor, thus making the USA a prominent market for orthopedic oncology.
China’s revenue generation on orthopedic oncology diagnosis in 2022 was US$ 105.0 Million.
According to Medical Express 2022, In the year 2022, China would have 4.82 million new instances of cancer and 3.21 million deaths due to cancer. The basic occurrence rate for primary bone malignancies was 1.76/100,000 Chinese standard population (ASIRC) as per Clinical Cases in Mineral and Bone Metabolism data from 2012.
China has a strong emphasis on research and development in the field of cancer treatment. As per an article in The Lancet Oncology 2021, The country invests significantly in medical research and clinical trials, and the development of innovative therapies. This focus on research and innovation attracts leading experts and encourages collaboration between the healthcare and pharmaceutical industries. Thus making China a highly lucrative market for orthopedic oncology.
In 2022, India held a dominant share of the East Asia market and contributed around US$ 87.9 Million.
The country's rapidly growing economic condition of the middle-class population has increased spending on healthcare and discretionary income. India has a well-developed healthcare system with excellent medical facilities, research institutions, and specialised cancer hospitals.
Recently, in January 2022, Ayushman Bharat approved bone marrow transplants, which are frequently advised to cancer patients. With a population of 1.4 billion, India has a high probability of orthopedic oncology cases. The healthcare scheme is a strength for the population with low socioeconomic backgrounds; as the government of India bears the maximum cost, more and more patients will opt for treatment, resulting in the growth of the orthopedic oncology market in India.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market value of diagnostics imaging used for diagnosis is US$ 715.1 Million, representing a sizable 62.3% global market share in 2022. Recently, the Musculoskeletal Tumour Society and the American Academy of Orthopedic Surgeons 2018, agreed upon a clinical practice suggestion titled Use of Imaging before Referral to an orthopedic oncologist.
In the absence of credible data, conventional radiographs are a reasonable diagnostic tool that should be explored during the first evaluation of a soft-tissue tumour. Diagnostics imaging is recommended in orthopedic oncology because it provides precise anatomical details, aids in staging and treatment planning, monitors therapy response and reduces invasiveness and patient pain.
Stage I of cancer contributes to 36.9% market share in 2022 and is expected to grow with a CAGR of 8.0%. In general, the initial stage of cancer is curable and has a higher possibility of success than the subsequent phases. As a result of the increased emphasis on detection and diagnosis, a greater percentage of patients are recognised and treated in stage I.
Medical technological advancements and growing awareness of the need for early diagnosis have resulted in enhanced screening procedures and increased involvement in cancer screening programmes.
By indications, osteosarcoma accounted for a predominant share of the global market, with a revenue share of 45.6% in 2022.
According to an article published in Société Internationale de Chirurgie Orthopédique et de Traumatologie 2018, Osteosarcoma (OS) is a type of main malignant bones tumour that affects 3.4 per million individuals globally each year. With an annual incidence of 5.6 cases per million adolescents below the age of 15, OS is the third most frequent cancer during adolescence, after only lymphomas and brain tumours. The greatest prevalence occurs during the second decade of adulthood.
Osteosarcoma was once assumed to be a radioresistant malignancy. However, advances in radiotherapy that makes it possible for the secure delivery of high doses of radiation are encouraging for patients with inoperable or insufficiently resected axial bones. It is aggressive and grows quickly, with an elevated risk and chance of spreading to other regions of the body; hence, it is prevalent in orthopedic oncology.
The hospitals have a considerable presence in the orthopedic oncology market, accounting for 48.9% of end users and exhibiting a prominent Compound Annual Growth Rate (CAGR) of 6.0%.
Hospitals are well-equipped with types of equipment and instruments for the diagnosis and treatment of orthopedic cancer. The doctors, nurses and other staff are readily available for treatment and care, and the patient with special care can be admitted to hospital wards. The physicians can observe and treat patients 24*7 in the hospital. Hence these factors make hospitals major benefitting end users in the market.
Collaborations and partnerships among hospitals, healthcare providers, research institutions, and technology businesses can encourage innovation and hasten orthopedic oncology diagnosis and treatment. Many pharmaceutical industries are involved in Research and Development and the development of drugs for the treatment of orthopedic cancer. Among the well-known players in this field are:
Deep learning is being used by the AI-powered platform to boost automation and make MRI scanning more efficient for hospitals dealing with concerns such as staff burnout and rising electricity expenditures.
The research institutions and medical schools have formed an innovative collaboration to advance personalised medicine and provide consumers with high-quality, cost-effective healthcare.
Similarly, recent developments related to the company’s active within the orthopedic oncology market space have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, India, Thailand, China, Indonesia, Malaysia, Japan, South Korea, Australia, New Zealand, GCC countries, Türkiye Northern Africa and South Africa. |
| Key Market Segments Covered | Diagnostic Techniques, Cancer Stage, Indications, End User, and Region |
| Key Companies Profiled |
|
| Report Coverage |
|
| Pricing | Available upon Request |
In 2023, the market is valued US$ 1.2 billion.
Until 2033, the market will experience a 6.5% CAGR.
Growing prevalence of bone and soft tissue tumors drives market growth.
Stage I will expand at an 8.0% CAGR through 2033.
General Electric (GE) Healthcare, Siemens Healthineers, and Koninklijke Philips N.V. are some key players.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Technology Roadmap 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Innovation / Development Trends 4. Value-Added Insights 4.1. Disease Epidemiology 4.2. Diagnostic Techniques Adoption/Usage Analysis 4.3. Regulatory Landscape, By Country 4.4. Reimbursement Scenario 4.5. Procedure Based Scenarios 4.6. Porter’s Analysis 4.7. PESTLE Analysis 4.8. Value Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global Healthcare Expenditure Outlook 5.1.2. Global Oncology Market Outlook (Parent Market) 5.2. Forecast Factors - Relevance & Impact 5.2.1. Rising Need for Diagnostic Technique 5.2.2. Increasing Prevalence of Cancer Cases 5.2.3. Growth of Clinical Diagnostics 5.2.4. Technological Advancements in Imaging 5.2.5. New Initiatives For Diagnostic Techniques Development 5.2.6. Cost of Diagnostic Equipment’s 5.2.7. Cost of the Treatment 5.2.8. Research and Development in Cancer Diagnostics 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 6.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022 6.2. Current and Future Market Size (US$ Million) Analysis and Forecast Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 6.2.2. Absolute $ Opportunity Analysis 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Diagnostic Techniques 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Million) Analysis By Diagnostic Techniques, 2017 to 2022 7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Diagnostic Techniques, 2023 to 2033 7.3.1. Diagnostic Imaging 7.3.1.1. X-ray Imaging 7.3.1.2. MRI Imaging 7.3.1.3. CT Imaging 7.3.1.4. PET Imaging 7.3.1.5. Ultrasound Imaging 7.3.2. Bone Biopsy 7.3.2.1. Biopsy Needles 7.3.2.2. Biopsy Trays & Kits 7.4. Market Attractiveness Analysis By Diagnostic Techniques 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Cancer Stage 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Cancer Stage, 2017 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Cancer Stage, 2023 to 2033 8.3.1. Stage I 8.3.2. Stage II 8.3.3. Stage III 8.3.4. Stage IV 8.4. Market Attractiveness Analysis By Cancer Stage 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis By Indication, 2017 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033 9.3.1. Osteosarcoma 9.3.2. Chondrosarcoma 9.3.3. Ewing Sarcoma 9.3.4. Chordroma 9.4. Market Attractiveness Analysis By Indication 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By End User, 2017 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033 10.3.1. Hospitals 10.3.2. Diagnostic Centres 10.3.3. Specialty Orthopedic Clinics 10.4. Market Attractiveness Analysis By End User 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2022 11.3. Current and Future Market Size (US$ Million) and Forecast By Region, 2023 to 2033 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. South Asia 11.3.5. East Asia 11.3.6. Oceania 11.3.7. Middle East and Africa 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 12.3.1. By Country 12.3.1.1. USA 12.3.1.2. Canada 12.3.2. By Diagnostic Techniques 12.3.3. By Cancer Stage 12.3.4. By Indication 12.3.5. By End User 12.4. Market Attractiveness Analysis By Region 12.4.1. By Country 12.4.2. By Diagnostic Techniques 12.4.3. By Cancer Stage 12.4.4. By Indication 12.4.5. By End User 12.5. Market trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 12.8. Country Level Analysis & Forecast 12.8.1. USA Market Analysis 12.8.1.1. Introduction 12.8.1.2. Market Analysis and Forecast by Market Taxonomy 12.8.1.2.1. By Diagnostic Techniques 12.8.1.2.2. By Cancer Stage 12.8.1.2.3. By Indication 12.8.1.2.4. By End User 12.8.2. Canada Market Analysis 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast by Market Taxonomy 12.8.2.2.1. By Diagnostic Techniques 12.8.2.2.2. By Cancer Stage 12.8.2.2.3. By Indication 12.8.2.2.4. By End User 13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13.1. Introduction / Key Findings 13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. Brazil 13.3.1.2. Mexico 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Diagnostic Techniques 13.3.3. By Cancer Stage 13.3.4. By Indication 13.3.5. By End User 13.4. Market Attractiveness Analysis By Region 13.4.1. By Country 13.4.2. By Diagnostic Techniques 13.4.3. By Cancer Stage 13.4.4. By Indication 13.4.5. By End User 13.5. Market trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. Brazil Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Diagnostic Techniques 13.8.1.2.2. By Cancer Stage 13.8.1.2.3. By Indication 13.8.1.2.4. By End User 13.8.2. Mexico Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Diagnostic Techniques 13.8.2.2.2. By Cancer Stage 13.8.2.2.3. By Indication 13.8.2.2.4. By End User 13.8.3. Argentina Market Analysis 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast by Market Taxonomy 13.8.3.2.1. By Diagnostic Techniques 13.8.3.2.2. By Cancer Stage 13.8.3.2.3. By Indication 13.8.3.2.4. Type By End User 14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14.1. Introduction / Key Findings 14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. France 14.3.1.3. Spain 14.3.1.4. Russia 14.3.1.5. Italy 14.3.1.6. BENELUX 14.3.1.7. Nordics 14.3.1.8. United Kingdom 14.3.1.9. Rest of Europe 14.3.2. By Diagnostic Techniques 14.3.3. By Cancer Stage 14.3.4. By Indication 14.3.5. By End User 14.4. Market Attractiveness Analysis By Region 14.4.1. By Country 14.4.2. By Diagnostic Techniques 14.4.3. By Cancer Stage 14.4.4. By Indication 14.4.5. By End User 14.5. Market trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. Germany Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Diagnostic Techniques 14.8.1.2.2. By Cancer Stage 14.8.1.2.3. By Indication 14.8.1.2.4. By End User 14.8.2. France Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Diagnostic Techniques 14.8.2.2.2. By Cancer Stage 14.8.2.2.3. By Indication 14.8.2.2.4. By End User 14.8.3. Spain Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Diagnostic Techniques 14.8.3.2.2. By Cancer Stage 14.8.3.2.3. By Indication 14.8.3.2.4. Type By End User 14.8.4. Russia Market Analysis 14.8.4.1. Introduction 14.8.4.2. Market Analysis and Forecast by Market Taxonomy 14.8.4.2.1. By Diagnostic Techniques 14.8.4.2.2. By Cancer Stage 14.8.4.2.3. By Indication 14.8.4.2.4. Type By End User 14.8.5. Italy Market Analysis 14.8.5.1. Introduction 14.8.5.2. Market Analysis and Forecast by Market Taxonomy 14.8.5.2.1. By Diagnostic Techniques 14.8.5.2.2. By Cancer Stage 14.8.5.2.3. By Indication 14.8.5.2.4. By End User 14.8.6. BENELUX Market Analysis 14.8.6.1. Introduction 14.8.6.2. Market Analysis and Forecast by Market Taxonomy 14.8.6.2.1. By Diagnostic Techniques 14.8.6.2.2. By Cancer Stage 14.8.6.2.3. By Indication 14.8.6.2.4. By End User 14.8.7. Nordics Market Analysis 14.8.7.1. Introduction 14.8.7.2. Market Analysis and Forecast by Market Taxonomy 14.8.7.2.1. By Diagnostic Techniques 14.8.7.2.2. By Cancer Stage 14.8.7.2.3. By Indication 14.8.7.2.4. By End User 14.8.8. United Kingdom Market Analysis 14.8.8.1. Introduction 14.8.8.2. Market Analysis and Forecast by Market Taxonomy 14.8.8.2.1. By Diagnostic Techniques 14.8.8.2.2. By Cancer Stage 14.8.8.2.3. By Indication 14.8.8.2.4. By End User 15. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15.1. Introduction / Key Findings 15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Indonesia 15.3.1.3. Thailand 15.3.1.4. Philippines 15.3.1.5. Malaysia 15.3.1.6. Vietnam 15.3.1.7. Rest of South Asia 15.3.2. By Diagnostic Techniques 15.3.3. By Cancer Stage 15.3.4. By Indication 15.3.5. By End User 15.4. Market Attractiveness Analysis By Region 15.4.1. By Country 15.4.2. By Diagnostic Techniques 15.4.3. By Cancer Stage 15.4.4. By Indication 15.4.5. By End User 15.5. Market trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. India Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Diagnostic Techniques 15.8.1.2.2. By Cancer Stage 15.8.1.2.3. By Indication 15.8.1.2.4. By End User 15.8.2. Indonesia Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Diagnostic Techniques 15.8.2.2.2. By Cancer Stage 15.8.2.2.3. By Indication 15.8.2.2.4. By End User 15.8.3. Thailand Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Diagnostic Techniques 15.8.3.2.2. By Cancer Stage 15.8.3.2.3. By Indication 15.8.3.2.4. By End User 15.8.4. Philippines Market Analysis 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast by Market Taxonomy 15.8.4.2.1. By Diagnostic Techniques 15.8.4.2.2. By Cancer Stage 15.8.4.2.3. By Indication 15.8.4.2.4. By End User 15.8.5. Malaysia Market Analysis 15.8.5.1. Introduction 15.8.5.2. Market Analysis and Forecast by Market Taxonomy 15.8.5.2.1. By Diagnostic Techniques 15.8.5.2.2. By Cancer Stage 15.8.5.2.3. By Indication 15.8.5.2.4. By End User 15.8.6. Vietnam Market Analysis 15.8.6.1. Introduction 15.8.6.2. Market Analysis and Forecast by Market Taxonomy 15.8.6.2.1. By Diagnostic Techniques 15.8.6.2.2. By Cancer Stage 15.8.6.2.3. By Indication 15.8.6.2.4. By End User 16. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16.1. Introduction / Key Findings 16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Diagnostic Techniques 16.3.3. By Cancer Stage 16.3.4. By Indication 16.3.5. By End User 16.4. Market Attractiveness Analysis By Region 16.4.1. By Country 16.4.2. By Diagnostic Techniques 16.4.3. By Cancer Stage 16.4.4. By Indication 16.4.5. By End User 16.5. Market trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. China Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Diagnostic Techniques 16.8.1.2.2. By Cancer Stage 16.8.1.2.3. By Indication 16.8.1.2.4. By End User 16.8.2. Japan Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Diagnostic Techniques 16.8.2.2.2. By Cancer Stage 16.8.2.2.3. By Indication 16.8.2.2.4. By End User 16.8.3. South Korea Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Diagnostic Techniques 16.8.3.2.2. By Cancer Stage 16.8.3.2.3. By Indication 16.8.3.2.4. By End User 17. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17.1. Introduction / Key Findings 17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Diagnostic Techniques 17.3.3. By Cancer Stage 17.3.4. By Indication 17.3.5. By End User 17.4. Market Attractiveness Analysis By Region 17.4.1. By Country 17.4.2. By Diagnostic Techniques 17.4.3. By Cancer Stage 17.4.4. By Indication 17.4.5. By End User 17.5. Market trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. Australia Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Diagnostic Techniques 17.8.1.2.2. By Cancer Stage 17.8.1.2.3. By Indication 17.8.1.2.4. By End User 17.8.2. New Zealand Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Diagnostic Techniques 17.8.2.2.2. By Cancer Stage 17.8.2.2.3. By Indication 17.8.2.2.4. By End User 18. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18.1. Introduction / Key Findings 18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Türkiye 18.3.1.3. South Africa 18.3.1.4. Northern Africa 18.3.1.5. Rest of Middle East and Africa 18.3.2. By Diagnostic Techniques 18.3.3. By Cancer Stage 18.3.4. By Indication 18.3.5. By End User 18.4. Market Attractiveness Analysis By Region 18.4.1. By Country 18.4.2. By Diagnostic Techniques 18.4.3. By Cancer Stage 18.4.4. By Indication 18.4.5. By End User 18.5. Market trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis & Forecast 18.8.1. GCC Countries Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Diagnostic Techniques 18.8.1.2.2. By Cancer Stage 18.8.1.2.3. By Indication 18.8.1.2.4. By End User 18.8.2. Türkiye Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Diagnostic Techniques 18.8.2.2.2. By Cancer Stage 18.8.2.2.3. By Indication 18.8.2.2.4. By End User 18.8.3. South Africa Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Diagnostic Techniques 18.8.3.2.2. By Cancer Stage 18.8.3.2.3. By Indication 18.8.3.2.4. By End User 18.8.4. Northern Africa Market Analysis 18.8.4.1. Introduction 18.8.4.2. Market Analysis and Forecast by Market Taxonomy 18.8.4.2.1. By Diagnostic Techniques 18.8.4.2.2. By Cancer Stage 18.8.4.2.3. By Indication 18.8.4.2.4. By End User 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Share Analysis of Top Players (%) 19.3. Market Presence Analysis 19.3.1. Regional Footprint of Players 19.3.2. Product Footprint of Players 19.3.3. Channel Footprint of Players 20. Competition Analysis 20.1. Competition Dashboard 20.2. Key Development Analysis 20.3. branding and Promotional Strategies, By Key Players 20.4. Competition Deep Dive 20.4.1. General Electric (GE) Healthcare. 20.4.1.1. Overview 20.4.1.2. Product Portfolio 20.4.1.3. Key Financials 20.4.1.4. Sales Footprint 20.4.1.5. Strategy Overview 20.4.1.5.1. Marketing Strategies 20.4.1.5.2. Channel Strategies 20.4.1.5.3. Product Strategies 20.4.2. Siemens Healthineers 20.4.2.1. Overview 20.4.2.2. Product Portfolio 20.4.2.3. Key Financials 20.4.2.4. Sales Footprint 20.4.2.5. Strategy Overview 20.4.2.5.1. Marketing Strategies 20.4.2.5.2. Channel Strategies 20.4.2.5.3. Product Strategies 20.4.3. Koninklijke Philips N.V. 20.4.3.1. Overview 20.4.3.2. Product Portfolio 20.4.3.3. Key Financials 20.4.3.4. Sales Footprint 20.4.3.5. Strategy Overview 20.4.3.5.1. Marketing Strategies 20.4.3.5.2. Channel Strategies 20.4.3.5.3. Product Strategies 20.4.4. Hitachi Medical Systems 20.4.4.1. Overview 20.4.4.2. Product Portfolio 20.4.4.3. Key Financials 20.4.4.4. Sales Footprint 20.4.4.5. Strategy Overview 20.4.4.5.1. Marketing Strategies 20.4.4.5.2. Channel Strategies 20.4.4.5.3. Product Strategies 20.4.5. Hologic 20.4.5.1. Overview 20.4.5.2. Product Portfolio 20.4.5.3. Key Financials 20.4.5.4. Sales Footprint 20.4.5.5. Strategy Overview 20.4.5.5.1. Marketing Strategies 20.4.5.5.2. Channel Strategies 20.4.5.5.3. Product Strategies 20.4.6. Shimadzu Medical Systems 20.4.6.1. Overview 20.4.6.2. Product Portfolio 20.4.6.3. Key Financials 20.4.6.4. Sales Footprint 20.4.6.5. Strategy Overview 20.4.6.5.1. Marketing Strategies 20.4.6.5.2. Channel Strategies 20.4.6.5.3. Product Strategies 20.4.7. Carestream Health 20.4.7.1. Overview 20.4.7.2. Product Portfolio 20.4.7.3. Key Financials 20.4.7.4. Sales Footprint 20.4.7.5. Strategy Overview 20.4.7.5.1. Marketing Strategies 20.4.7.5.2. Channel Strategies 20.4.7.5.3. Product Strategies 20.4.8. Canon Medical Systems 20.4.8.1. Overview 20.4.8.2. Product Portfolio 20.4.8.3. Key Financials 20.4.8.4. Sales Footprint 20.4.8.5. Strategy Overview 20.4.8.5.1. Marketing Strategies 20.4.8.5.2. Channel Strategies 20.4.8.5.3. Product Strategies 20.4.9. FUJIFILM Medical Systems 20.4.9.1. Overview 20.4.9.2. Product Portfolio 20.4.9.3. Key Financials 20.4.9.4. Sales Footprint 20.4.9.5. Strategy Overview 20.4.9.5.1. Marketing Strategies 20.4.9.5.2. Channel Strategies 20.4.9.5.3. Product Strategies 20.4.10. Ziehm Imaging 20.4.10.1. Overview 20.4.10.2. Product Portfolio 20.4.10.3. Key Financials 20.4.10.4. Sales Footprint 20.4.10.5. Strategy Overview 20.4.10.5.1. Marketing Strategies 20.4.10.5.2. Channel Strategies 20.4.10.5.3. Product Strategies 20.4.11. Planmed Oy 20.4.11.1. Overview 20.4.11.2. Product Portfolio 20.4.11.3. Key Financials 20.4.11.4. Sales Footprint 20.4.11.5. Strategy Overview 20.4.11.5.1. Marketing Strategies 20.4.11.5.2. Channel Strategies 20.4.11.5.3. Product Strategies 20.4.12. EOS imaging 20.4.12.1. Overview 20.4.12.2. Product Portfolio 20.4.12.3. Key Financials 20.4.12.4. Sales Footprint 20.4.12.5. Strategy Overview 20.4.12.5.1. Marketing Strategies 20.4.12.5.2. Channel Strategies 20.4.12.5.3. Product Strategies 20.4.13. Medtronic plc 20.4.13.1. Overview 20.4.13.2. Product Portfolio 20.4.13.3. Key Financials 20.4.13.4. Sales Footprint 20.4.13.5. Strategy Overview 20.4.13.5.1. Marketing Strategies 20.4.13.5.2. Channel Strategies 20.4.13.5.3. Product Strategies 20.4.14. Stryker Corporation 20.4.14.1. Overview 20.4.14.2. Product Portfolio 20.4.14.3. Key Financials 20.4.14.4. Sales Footprint 20.4.14.5. Strategy Overview 20.4.14.5.1. Marketing Strategies 20.4.14.5.2. Channel Strategies 20.4.14.5.3. Product Strategies 20.4.15. Cook Medical 20.4.15.1. Overview 20.4.15.2. Product Portfolio 20.4.15.3. Key Financials 20.4.15.4. Sales Footprint 20.4.15.5. Strategy Overview 20.4.15.5.1. Marketing Strategies 20.4.15.5.2. Channel Strategies 20.4.15.5.3. Product Strategies 20.4.16. Zimmer Biomet 20.4.16.1. Overview 20.4.16.2. Product Portfolio 20.4.16.3. Key Financials 20.4.16.4. Sales Footprint 20.4.16.5. Strategy Overview 20.4.16.5.1. Marketing Strategies 20.4.16.5.2. Channel Strategies 20.4.16.5.3. Product Strategies 20.4.17. Biopsybell 20.4.17.1. Overview 20.4.17.2. Product Portfolio 20.4.17.3. Key Financials 20.4.17.4. Sales Footprint 20.4.17.5. Strategy Overview 20.4.17.5.1. Marketing Strategies 20.4.17.5.2. Channel Strategies 20.4.17.5.3. Product Strategies 20.4.18. Becton Dickenson & Company 20.4.18.1. Overview 20.4.18.2. Product Portfolio 20.4.18.3. Key Financials 20.4.18.4. Sales Footprint 20.4.18.5. Strategy Overview 20.4.18.5.1. Marketing Strategies 20.4.18.5.2. Channel Strategies 20.4.18.5.3. Product Strategies 20.4.19. Teleflex Inc. 20.4.19.1. Overview 20.4.19.2. Product Portfolio 20.4.19.3. Key Financials 20.4.19.4. Sales Footprint 20.4.19.5. Strategy Overview 20.4.19.5.1. Marketing Strategies 20.4.19.5.2. Channel Strategies 20.4.19.5.3. Product Strategies 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Orthopedic Oncology Market
